What Vivitrol Treats: Main Uses and Benefits

The primary role of Vivitrol in a comprehensive management program plays a role in managing the symptoms that contribute to dependence and the risk of relapse. The medication is commonly used for the treatment of Alcohol Use Disorder (AUD) and the prevention of relapse to Opioid Use Disorder (OUD) in adult patients.

Support and Symptom Management

The medication is relevant for easing the symptoms related to chronic dependence, specifically the intense, recurrent cravings for alcohol and opioids, which may interfere with functional stability. This treatment is commonly used in the post-detoxification clinical context where additional symptomatic support is needed. This supportive therapeutic benefit may assist with managing the symptomatic patterns of heavy drinking and provides supportive relief when symptoms become more noticeable.

Easing this symptomatic strain assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations during the recovery process.

---

Quick Fact: Therapeutic Use

Vivitrol is applied in addressing the pronounced and often disruptive symptoms of substance cravings and recurrent urges, contributing to improved comfort during symptomatic phases.

Official Eligibility and Non-Eligibility Rules

Regulatory labeling dictates specific conditions that determine who is eligible to use Vivitrol (naltrexone extended-release injectable suspension) and who must be excluded. The primary constraint involves a patient’s current opioid status.

Classification	Population Status	Regulatory Condition
Contraindicated	Current physiologic opioid dependence	Must not be receiving opioid analgesics, be in acute withdrawal, or have a positive opioid urine screen or failed naloxone challenge test.
Prohibited Status	Severe liver dysfunction	Contraindicated in patients with acute hepatitis or liver failure. Use should be discontinued if signs of acute hepatitis occur.
Required Pre-Condition	Opioid Use Disorder	Must be verified as opioid-free for a minimum duration of 7 to 14 days prior to the first injection to prevent precipitated withdrawal.
Age Restriction	Pediatric population (under 18 years)	Safety and effectiveness are not established. Use is limited to adult patients.
Conditional Use	Pregnancy status	Classified as Pregnancy Category C; use is allowed only if the expected benefit outweighs the potential risk to the fetus.
Conditional Use	Renal impairment	Caution is recommended when administering to patients with moderate to severe renal impairment, as data is limited.

Eligibility is strictly limited to adult patients who meet the mandatory opioid-free pre-condition and do not possess any of the documented contraindications, particularly those related to active opioid use or severe liver impairment.

Interactions with other medicines and products

The primary concern for drug interactions with Vivitrol (naltrexone extended-release injectable suspension) is its direct action as an opioid receptor antagonist. This mechanism means the medicine will block the effects of any opioid-containing products.

---

Interacting Products and Associated Risks

Interaction Domain	Relevant Product Categories
Opioid Antagonism	Opioid analgesics, opioid-containing cough/cold remedies, antidiarrheal preparations, and opioid dependence treatments (e.g., buprenorphine, methadone).

Official Interaction Statements

• Contraindicated Use: Vivitrol is contraindicated in patients who are receiving opioid analgesics, have current physiologic opioid dependence, or are in acute opioid withdrawal. It is also contraindicated if an individual fails a naloxone challenge test or has a positive urine screen for opioids.
• Withdrawal Precaution: To avoid the unintended and potentially severe precipitation of opioid withdrawal, patients must be opioid-free for a minimum of 7 to 14 days prior to the initial dose.
• Risk of Fatal Overdose: The blocking effect of the medicine is potentially surmountable. Attempts to overcome the antagonism by taking large amounts of exogenous opioids can lead to serious injury, coma, or fatal overdose.
• Reduced Tolerance: Patients are more sensitive to the effects of lower doses of opioids after Vivitrol treatment is discontinued, at the end of a dosing interval, or after a missed dose, due to a reduced opioid tolerance. This increased sensitivity carries a risk of potentially fatal overdose.

Official regulatory documents emphasize the need to strictly avoid all forms of opioids due to the competitive receptor blockade and the risks of precipitated withdrawal and subsequent overdose vulnerability.

Vivitrol, a formulation of the mu-opioid receptor (mu-OR) mathbfantagonist naltrexone, functions by competitively binding to opioid receptors throughout the central and peripheral nervous systems. The primary biological target is the G-protein-coupled mu-OR, although naltrexone also exhibits high affinity for the kappa-opioid receptor (kappa-OR) and moderate affinity for the delta-opioid receptor (delta-OR).

Naltrexone acts as a pure antagonist, lacking intrinsic activity and thereby preventing the binding and subsequent activation of these receptors by endogenous opioid peptides (e.g., endorphins, enkephalins) and exogenous opioid molecules. This competitive inhibition interrupts the typical signaling cascade. Binding of the drug to the mu-OR stabilizes the receptor in an inactive conformation. This action prevents the dissociation of the G i/ o protein heterotrimer and subsequent inhibition of adenylyl cyclase. The block on adenylyl cyclase inhibition prevents the typical opioid-induced decrease in cAMP production, thus maintaining baseline cellular excitability.

At a system level, the mechanism results in non-activation of the mesolimbic and mesocortical dopamine pathways that are typically modulated by mu-OR activation.

Administration Process

Vivitrol is administered as an intramuscular injection into the gluteal muscle. The procedure is performed by a healthcare professional in a medical setting. To ensure consistent therapeutic levels of the medication, the injection is typically given once every four weeks or once a month.

The administration alternates between the left and right buttock for each subsequent dose to minimize local tissue irritation. The medication is supplied as a powder that must be reconstituted with a specific diluent immediately before use.

Requirements Before Starting Treatment

Prior to the first administration, individuals must undergo a detoxification period to ensure the body is free from opioids. Starting the medication while opioids are still present in the system can precipitate sudden and severe withdrawal symptoms.

Healthcare providers may use various methods to confirm a patient is ready for treatment, which may include:

• Review of recent medication history: Assessing the time elapsed since the last use of any opioid-containing substances.
• Clinical assessment: Evaluating the patient for any current signs of opioid withdrawal.
• Urine screening: Testing for the presence of opioids in the system.
• Naloxone challenge test: In some cases, a brief provocative test is used to verify that opioid receptors are clear.

Treatment Continuity and Monitoring

Consistency is a key factor in the management of the condition for which Vivitrol is prescribed. If a scheduled appointment is missed, the next dose should be administered as soon as possible.

Ongoing treatment involves regular consultations with a healthcare provider to monitor the patient's progress and overall response to the medication. Because this medication is part of a comprehensive treatment plan, it is often used in conjunction with counseling, support groups, or other therapeutic interventions.

Vivitrol: Recent Clinical Evidence

Research Evidence for Opioid Use Disorder

Research for opioid use disorder relies primarily on Randomized Controlled Trials (RCTs) that explored the medicine’s use in preventing relapse following detoxification. These studies compared the injectable medicine against a placebo. Studies included adult outpatients who had completed an opioid-free period before starting the medication. Researchers monitored outcomes related to opioid abstinence (confirmed by lab tests) and opioid craving severity over defined intervals, typically six months. Studies also monitored treatment retention. Results apply primarily to the study populations meeting the abstinence requirement.

---

Research Evidence for Alcohol Use Disorder

The evidence for alcohol use disorder has been explored through randomized controlled trials and reviews examining this data. These studies focused on adult outpatients, monitoring outcomes such as the reduction in heavy drinking days and rates of complete abstinence. Findings related to these outcomes were often more apparent in the subset of patients who began the study with a period of initial abstinence. Comparative evidence against a placebo is significant, but research exploring long-term effects beyond six months is limited.

---

Evidence Limitations and Context

The overall evidence base relies significantly on studies comparing the medicine against a placebo. Research gaps exist regarding its performance versus other medications used in research exploring opioid use disorder and long-term data for both indications. For both OUD and AUD, the requirement of an initial abstinence period was observed to affect entry into the study, which restricts the applicability of the results primarily to patients who met this criteria. Data for certain groups, such as older adults, remain insufficient, and subgroup findings are generally uncertain due to small sample sizes.

Common questions about Vivitrol (FAQ)

Q: How long does Vivitrol take to work after the first injection?

A: Official information regarding the medicine's absorption indicates that the active ingredient, naltrexone, reaches its first peak level in the blood about two hours after the injection. A second peak level is reached approximately two to three days later. Measurable levels of the medication can remain in the body for over one month, consistent with the intended monthly dosing schedule.

Q: Does Vivitrol have a generic version available?

A: The specific extended-release injectable suspension formulation is currently available only under the brand name Vivitrol. However, the immediate-release form of naltrexone that is taken by mouth is available in generic tablet form.

Q: Is Vivitrol considered a narcotic, addictive, or controlled substance?

A: According to official regulatory classifications, Vivitrol (naltrexone) is not categorized as a controlled substance. It is designated as a non-narcotic and non-addictive agent, meaning it does not carry the risk of physical dependence.

Q: Can I drink alcohol while taking Vivitrol?

A: Vivitrol is officially approved to support the treatment of alcohol dependence. Official product labeling indicates that the use of this medicine for alcohol dependence is meant for patients who are able to abstain from alcohol.

Q: Can I get pregnant while taking Vivitrol?

A: The medicine is classified as Pregnancy Category C. The decision to use it during pregnancy involves balancing the potential benefit against any potential risk, as information suggests. Regulatory information does not confirm whether the medicine affects fertility in humans.

Q: What should I do if I miss an appointment to get my monthly injection?

A: Official medication guidance suggests that if a scheduled injection appointment is missed, the patient should receive the next dose as soon as feasible. Missing a dose may result in lower drug levels, which may potentially increase the risk for relapse.

Official Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and handling of the Vivitrol dose pack.

Storage Classification	Requirement
Temperature	The entire dose pack must be stored in a refrigerator (2°C to 8°C or 36°F to 46°F).
Freezing	Do not freeze.
Temporary Storage	Can be held at temperatures not exceeding 25°C (77°F) for a maximum of 7 days.

Handling and Stability

Prior to preparation, the product must be allowed to reach room temperature (approximately 45 minutes). Once the medication is reconstituted by a healthcare professional, the suspension must be administered immediately due to stability requirements. Vivitrol must only be injected using the customized needles supplied in the dose pack.

Disposal

All components of the dose pack, including the used needles and vials, must be disposed of by the healthcare facility according to established federal, state, and local regulations for sharps and pharmaceutical waste.